These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24325386)

  • 1. Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial.
    Hatamkhani S; Khalili H; Karimzadeh I; Dashti-Khavidaki S; Abdollahi A; Jafari S
    J Gastroenterol Hepatol; 2014 May; 29(5):997-1004. PubMed ID: 24325386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria.
    Aishatu G; Rasheedah I; Wahab J; Sheni M; Damilola O; Adeniyi O
    Ethiop J Health Sci; 2017 Mar; 27(2):115-120. PubMed ID: 28579706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
    Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
    Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial.
    Zhang S; Pan H; Peng X; Lu H; Fan H; Zheng X; Xu G; Wang M; Wang J
    J Gastroenterol Hepatol; 2016 Feb; 31(2):409-16. PubMed ID: 26243373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection.
    Fountain FF; Tolley EA; Jacobs AR; Self TH
    Am J Med Sci; 2009 May; 337(5):317-20. PubMed ID: 19295414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early monitoring for detection of antituberculous drug-induced hepatotoxicity.
    Lee CM; Lee SS; Lee JM; Cho HC; Kim WS; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ
    Korean J Intern Med; 2016 Jan; 31(1):65-72. PubMed ID: 26767859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.
    Sarda P; Sharma SK; Mohan A; Makharia G; Jayaswal A; Pandey RM; Singh S
    Indian J Med Res; 2009 Jan; 129(1):64-7. PubMed ID: 19287059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
    Fountain FF; Tolley E; Chrisman CR; Self TH
    Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity.
    Coca NS; Oliveira MS; Voieta I; Antunes CM; Lambertucci JR
    Rev Soc Bras Med Trop; 2010; 43(6):624-8. PubMed ID: 21181011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.
    Saito Z; Kaneko Y; Kinoshita A; Kurita Y; Odashima K; Horikiri T; Yoshii Y; Seki A; Seki Y; Takeda H; Kuwano K
    BMC Infect Dis; 2016 Nov; 16(1):668. PubMed ID: 27835982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
    Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
    Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients.
    Nanashima K; Mawatari T; Tahara N; Higuchi N; Nakaura A; Inamine T; Kondo S; Yanagihara K; Fukushima K; Suyama N; Kohno S; Tsukamoto K
    Tuberculosis (Edinb); 2012 May; 92(3):253-9. PubMed ID: 22341855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs.
    Chamorro JG; Castagnino JP; Musella RM; Nogueras M; Aranda FM; Frías A; Visca M; Aidar O; Perés S; de Larrañaga GF
    J Gastroenterol Hepatol; 2013 Feb; 28(2):323-8. PubMed ID: 23190413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
    Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
    Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.